Logo image of ASND

ASCENDIS PHARMA A/S - ADR (ASND) Stock Fundamental Analysis

NASDAQ:ASND - Nasdaq - US04351P1012 - ADR - Currency: USD

152.43  -2.15 (-1.39%)

After market: 152.43 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ASND. ASND was compared to 572 industry peers in the Biotechnology industry. Both the profitability and financial health of ASND have multiple concerns. ASND is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

ASND had negative earnings in the past year.
In the past year ASND has reported a negative cash flow from operations.
In the past 5 years ASND always reported negative net income.
ASND had a negative operating cash flow in each of the past 5 years.
ASND Yearly Net Income VS EBIT VS OCF VS FCFASND Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M -400M -500M

1.2 Ratios

ASND has a Return On Assets of -32.05%. This is in the better half of the industry: ASND outperforms 65.01% of its industry peers.
Industry RankSector Rank
ROA -32.05%
ROE N/A
ROIC N/A
ROA(3y)-47.96%
ROA(5y)-44.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ASND Yearly ROA, ROE, ROICASND Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200

1.3 Margins

ASND has a Gross Margin of 87.83%. This is amongst the best in the industry. ASND outperforms 91.12% of its industry peers.
ASND's Gross Margin has improved in the last couple of years.
ASND does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 87.83%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y17.06%
GM growth 5YN/A
ASND Yearly Profit, Operating, Gross MarginsASND Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

1

2. Health

2.1 Basic Checks

ASND does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ASND has more shares outstanding
The number of shares outstanding for ASND has been increased compared to 5 years ago.
The debt/assets ratio for ASND has been reduced compared to a year ago.
ASND Yearly Shares OutstandingASND Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
ASND Yearly Total Debt VS Total AssetsASND Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

ASND has an Altman-Z score of 0.71. This is a bad value and indicates that ASND is not financially healthy and even has some risk of bankruptcy.
ASND's Altman-Z score of 0.71 is fine compared to the rest of the industry. ASND outperforms 65.36% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 0.71
ROIC/WACCN/A
WACC6.29%
ASND Yearly LT Debt VS Equity VS FCFASND Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M 800M

2.3 Liquidity

A Current Ratio of 1.17 indicates that ASND should not have too much problems paying its short term obligations.
The Current ratio of ASND (1.17) is worse than 85.61% of its industry peers.
ASND has a Quick Ratio of 1.17. This is a bad value and indicates that ASND is not financially healthy enough and could expect problems in meeting its short term obligations.
ASND has a Quick ratio of 0.84. This is amonst the worse of the industry: ASND underperforms 90.05% of its industry peers.
Industry RankSector Rank
Current Ratio 1.17
Quick Ratio 0.84
ASND Yearly Current Assets VS Current LiabilitesASND Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 23.25% over the past year.
ASND shows a strong growth in Revenue. In the last year, the Revenue has grown by 36.34%.
Measured over the past years, ASND shows a very strong growth in Revenue. The Revenue has been growing by 93.57% on average per year.
EPS 1Y (TTM)23.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.44%
Revenue 1Y (TTM)36.34%
Revenue growth 3Y260.22%
Revenue growth 5Y93.57%
Sales Q2Q%26.3%

3.2 Future

Based on estimates for the next years, ASND will show a very strong growth in Earnings Per Share. The EPS will grow by 36.05% on average per year.
The Revenue is expected to grow by 52.26% on average over the next years. This is a very strong growth
EPS Next Y40.97%
EPS Next 2Y47.47%
EPS Next 3Y43.61%
EPS Next 5Y36.05%
Revenue Next Year79.11%
Revenue Next 2Y80.39%
Revenue Next 3Y71.67%
Revenue Next 5Y52.26%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ASND Yearly Revenue VS EstimatesASND Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B
ASND Yearly EPS VS EstimatesASND Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 10 -10 20

1

4. Valuation

4.1 Price/Earnings Ratio

ASND reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ASND is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ASND Price Earnings VS Forward Price EarningsASND Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ASND Per share dataASND EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6 -6

4.3 Compensation for Growth

ASND's earnings are expected to grow with 43.61% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y47.47%
EPS Next 3Y43.61%

0

5. Dividend

5.1 Amount

No dividends for ASND!.
Industry RankSector Rank
Dividend Yield N/A

ASCENDIS PHARMA A/S - ADR

NASDAQ:ASND (2/21/2025, 8:01:58 PM)

After market: 152.43 0 (0%)

152.43

-2.15 (-1.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-12 2025-02-12/amc
Earnings (Next)04-30 2025-04-30/amc
Inst Owners110.13%
Inst Owner Change-91.79%
Ins Owners0.78%
Ins Owner ChangeN/A
Market Cap9.12B
Analysts87.27
Price Target207.06 (35.84%)
Short Float %5.55%
Short Ratio7.5
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)18.8%
Min EPS beat(2)3.09%
Max EPS beat(2)34.5%
EPS beat(4)2
Avg EPS beat(4)-11.98%
Min EPS beat(4)-50.09%
Max EPS beat(4)34.5%
EPS beat(8)5
Avg EPS beat(8)0.52%
EPS beat(12)6
Avg EPS beat(12)-2.69%
EPS beat(16)9
Avg EPS beat(16)3.08%
Revenue beat(2)1
Avg Revenue beat(2)5.64%
Min Revenue beat(2)-31.16%
Max Revenue beat(2)42.44%
Revenue beat(4)2
Avg Revenue beat(4)-7.11%
Min Revenue beat(4)-57.97%
Max Revenue beat(4)42.44%
Revenue beat(8)5
Avg Revenue beat(8)20.09%
Revenue beat(12)9
Avg Revenue beat(12)24.15%
Revenue beat(16)11
Avg Revenue beat(16)20.23%
PT rev (1m)3.92%
PT rev (3m)5.15%
EPS NQ rev (1m)3.64%
EPS NQ rev (3m)-469.58%
EPS NY rev (1m)9.12%
EPS NY rev (3m)-0.31%
Revenue NQ rev (1m)7.53%
Revenue NQ rev (3m)-43.7%
Revenue NY rev (1m)6.54%
Revenue NY rev (3m)1.72%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 23.96
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-6.88
EYN/A
EPS(NY)-4.06
Fwd EYN/A
FCF(TTM)-5.38
FCFYN/A
OCF(TTM)-5.36
OCFYN/A
SpS6.36
BVpS-1.85
TBVpS-1.92
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -32.05%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 87.83%
FCFM N/A
ROA(3y)-47.96%
ROA(5y)-44.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y17.06%
GM growth 5YN/A
F-Score4
Asset Turnover0.31
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 8.06%
Cap/Sales 0.39%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.17
Quick Ratio 0.84
Altman-Z 0.71
F-Score4
WACC6.29%
ROIC/WACCN/A
Cap/Depr(3y)33.9%
Cap/Depr(5y)97.41%
Cap/Sales(3y)9.88%
Cap/Sales(5y)130.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.44%
EPS Next Y40.97%
EPS Next 2Y47.47%
EPS Next 3Y43.61%
EPS Next 5Y36.05%
Revenue 1Y (TTM)36.34%
Revenue growth 3Y260.22%
Revenue growth 5Y93.57%
Sales Q2Q%26.3%
Revenue Next Year79.11%
Revenue Next 2Y80.39%
Revenue Next 3Y71.67%
Revenue Next 5Y52.26%
EBIT growth 1Y38.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year41.71%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y34.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y34.48%
OCF growth 3YN/A
OCF growth 5YN/A